GTHX has leaned way out over the front of their skis. Eg on this terminated trial they had not done a ph2, or indeed had any human data in this protocol or adjacent. They just relied on a speculative MOA w very sketchy data.
They are similarly ahead of themselves on the upcoming ph3 interim result. Huge change in protocol/population from ph2 and massively underpowered (it’s effectively two entirely separate trials in a single trial).
It’s a pity because it’s an interesting drug. It’s probably the single best poster child for the biotech aphorism that ‘even with a very good drug you need better than average management (similarly … vice versa)’.
News 
Market Data 
Discover 
AI
